A new Periodic Transaction Report filed under the STOCK Act shows that the spouse of Hon. Richard W. Allen, a member of the U.S. House of Representatives, sold shares of Abbott Laboratories (ABT) common stock on July 14, 2026. The transaction, disclosed in a range between $15,001 and $50,000, was executed through the LIVTR brokerage platform. Our system classifies this filing as a congress sale signal.
STOCK Act disclosures like this one are required by law for members of Congress and their immediate family when they buy or sell individual securities above a certain threshold. The filing itself is not an accusation of wrongdoing; it is simply a transparency mechanism that lets the public see when lawmakers or their households have financial exposure to companies that may be affected by federal policy, appropriations, or regulatory decisions.
A Notable Cross-Signal
What makes this filing worth flagging is its timing relative to activity inside Abbott Laboratories itself. Company insider Morrone Louis H. also sold ABT shares, filing a Form 4 for a sale worth $642,506 on August 11, 2026 — within roughly 30 days of Rep. Allen’s spousal transaction. When a congressional sale and a company insider sale land close together on the same ticker, it does not indicate coordination or any shared motive, but it is the kind of overlapping pattern that our tracking tools are built to surface for readers who follow both political and corporate trading disclosures side by side.
Abbott Laboratories has also shown up in other recent congressional filings. Earlier this cycle, we covered a separate transaction involving Rep. Richard McCormick’s sale of Abbott Labs (ABT) stock, which adds another data point to the broader pattern of ABT appearing across multiple members’ disclosures in recent weeks. Readers tracking the stock may find it useful to compare the dates and amounts across these separate filings.
For context, Abbott Laboratories is a diversified healthcare company with businesses spanning diagnostics, medical devices, nutrition, and branded generic pharmaceuticals, making it a stock that intersects with several areas of federal healthcare policy and regulation — one reason it periodically appears in both congressional and insider trading disclosures.
As always with these filings, the disclosed amount is a range rather than an exact figure, and the transaction was made by a spouse rather than the member directly. Neither detail changes the legal reporting obligation, but both are worth keeping in mind when reading the raw numbers. We will continue monitoring ABT-related filings, including any follow-up disclosures tied to this reporting window, and will update coverage if additional transactions emerge.